Australia - Kiingereza - APVMA (Australian Pesticides and Veterinary Medicines Authority)

fosterra pty ltd - bromoxynil present as the n-octanoyl ester; mcpa present as the ethyl hexyl ester; liquid hydrocarbon - emulsifiable concentrate - bromoxynil present as the n-octanoyl ester nitrile active 200.0 g/l; mcpa present as the ethyl hexyl ester phenoxy acids-mcpa-ester active 200.0 g/l; liquid hydrocarbon solvent other 343.0 g/l - herbicide - barley | bent grass | buffalo grass lawn or turf | cereal rye | couch - established | fescue lawn or turf | grass pasture | kiku - amsinckia | bindy-eye | black bindweed | capeweed | cat's ears or flatweeds | chamomile or matricaria | charlock | cleavers | clover | common peppercress | corn gromwell, ironweed or sheepweed | creeping buttercup | cudweed | dandelion - taraxacum officinale | fat hen | field madder | fleabane | fumitory | horned poppy | indian hedge mustard | jo-jo | lesser swinecress or bittercress | melilotus or hexham scent | mexican poppy | mintweed | mountain sorrel | mountain sorrel/purple calandrinia | mustard | oxalis spp. | paterson's curse | plantain | rough poppy | saffron thistle | shepherd's purse | slender, shore or sheep thistle | sow or milk thistle | thistle | three cornered jack or doublegee | three-horned bedstraw | tree hogweed | turnip weed | variegated thistle | wild radish or radish weed | wild turnip | wireweed, knotweed or hogweed | annual bindweed | annual flatweed | bilderdykia convolvulus | bindii | bindy-eye | blessed thistle | blue field madder | blue salvia | bogan flea | brassica campestris |

Australia - Kiingereza - APVMA (Australian Pesticides and Veterinary Medicines Authority)

fosterra pty ltd - trifluralin; liquid hydrocarbon - emulsifiable concentrate - trifluralin anilide/aniline-dinitro active 480.0 g/l; liquid hydrocarbon solvent other 495.0 g/l - herbicide - adzuki bean | annual medic seed crop-prior to sowing | barley | barley - prior to sowing | barley - prior to sowing & incorporat - amaranth or amaranthus | amsinckia,yellow burrweed or burr grass | annual broadleaf weed | annual grass weed | annual phalaris | annual ryegrass | annual ryegrass - seed | annual ryegrass - suppression | barley grass | barnyard or water grass | barnyard or water grass - seed | black bindweed - suppression | brome grass | brome grass - suppression | button grass | caltrop - tribulis terrestis | caltrop or yellow vine | caltrop or yellow vine - seed | caltrop or yellow vine - suppression | canary grass | canary grass - seed | capeweed | cereal oat | cereal oats - suppression | columbus grass - seed | common fumitory | corn gromwell, ironweed or sheepweed | crowsfoot grass | deadnettle | deadnettle - suppression | doublegee - suppression | fumitory | fumitory - red | fumitory - seed | fumitory - suppression | fumitory - white | geranium | giant or black pigweed | guinea grass - seed | iceplant - suppression | indian hedge mustard | ivy leaf speedwell | johnson grass - seed | liverseed grass - seed | lovegrass |

India - Kiingereza - Central Drugs Standard Control Organization

shantha bio. - amifostine - vial - 500mg - 1

Umoja wa Ulaya - Kiingereza - EMA (European Medicines Agency)

instituto grifols s.a. - fostamatinib disodium - thrombocytopenia - other systemic hemostatics - tavlesse is indicated for the treatment of chronic immune thrombocytopenia (itp) in adult patients who are refractory to other treatments.

Marekani - Kiingereza - NLM (National Library of Medicine)

viiv healthcare company - fostemsavir tromethamine (unii: 2x513p36u0) (temsavir - unii:4b6j53w8n3) - rukobia, in combination with other antiretroviral(s), is indicated for the treatment of human immunodeficiency virus type 1 (hiv-1) infection in heavily treatment-experienced adults with multidrug-resistant hiv-1 infection failing their current antiretroviral regimen due to resistance, intolerance, or safety considerations [see clinical studies (14)]. rukobia is contraindicated in patients: pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in individuals exposed to rukobia during pregnancy. healthcare providers are encouraged to register patients by calling the antiretroviral pregnancy registry (apr) at 1-800-258-4263. risk summary there are insufficient human data on the use of rukobia during pregnancy to adequately assess a drug-associated risk of birth defects and miscarriage. in animal reproduction studies, oral administration of fostemsavir to pregnant rats and rabbits during organogenesis resulted in no adverse developmental effects at clinically relevant temsavir exposures (see data) . the background risk for major birth defects and miscarriage for the indicated population is unknown. the background rate for major birth defects in a u.s. reference population of the metropolitan atlanta congenital defects program (macdp) is 2.7%. the estimated background rate of miscarriage in clinically recognized pregnancies in the u.s. general population is 15% to 20%. data animal data: fostemsavir was administered orally to pregnant rats (50, 200, 600 mg/kg/day) and rabbits (25, 50, or 100 mg/kg/day) during gestation days 6 to 15 (rat) and 7 to 19 (rabbit). no fetal abnormalities were observed at temsavir exposures of approximately 180 (rat) and 30 (rabbit) times those in humans at the maximum recommended human dose (mrhd). in rabbits, increased embryonic death associated with maternal toxicity was observed at temsavir exposures approximately 60 times those in humans at the mrhd. in a separate rat study conducted at drug exposures approximately 200 times those in humans at the mrhd, fetal abnormalities (cleft palate, open eyes, shortened snout, microstomia, misaligned mouth/jaw, and protruding tongue) and reductions in fetal body weights occurred in the presence of maternal toxicity. in a rat pre- and postnatal development study, fostemsavir was administered orally at doses of 10, 50, or 300 mg/kg/day from gestation day 6 through lactation day 20. reduced neonatal survival (7 to 14 days after birth) in the absence of other adverse fetal or neonatal effects was observed at maternal temsavir exposures approximately 130 times those in humans at the mrhd. no adverse fetal or neonatal effects were observed at maternal temsavir exposures approximately 35 times those in humans at the mrhd. in a distribution study in pregnant rats, fostemsavir-related drug materials (i.e., temsavir and/or temsavir-derived metabolites) crossed the placenta and were detectable in fetal tissue. risk summary it is not known whether rukobia is present in human breast milk, affects human milk production, or has effects on the breastfed infant. when administered to lactating rats, fostemsavir-related drug was present in rat milk (see data) . when a drug is present in animal milk, it is likely that the drug will be present in human milk. potential risks of breastfeeding include: (1) hiv-1 transmission (in hiv-1–negative infants), (2) developing viral resistance (in hiv-1–positive infants), and (3) adverse reactions in a breastfed infant similar to those seen in adults. data in a distribution study, fostemsavir-related drug materials (i.e., temsavir and/or temsavir-derived metabolites) were excreted in rat milk following a single dose of fostemsavir administered to lactating rats 7 to 9 days postpartum. in the pre- and postnatal development study in rats, temsavir was present in milk at concentrations similar to those measured in maternal plasma, as determined 11 days postpartum. in addition, lactational exposure was associated with reduced offspring survival at maternal temsavir exposures not thought to be clinically relevant. the safety and effectiveness of rukobia have not been established in pediatric patients. clinical trials of rukobia did not include sufficient numbers of subjects aged 65 and older to determine whether they respond differently from younger subjects. in general, caution should be exercised in administration of rukobia in elderly patients reflecting greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy [see clinical pharmacology (12.3)]. elderly patients may be more susceptible to drug-induced qt interval prolongation [see warnings and precautions (5.2)]. no dosage adjustment is required for patients with renal impairment or those on hemodialysis [see clinical pharmacology (12.3)] . no dosage adjustment is required in patients with mild to severe hepatic impairment (child-pugh score a, b, or c) [see clinical pharmacology (12.3)] .

Kanada - Kiingereza - Health Canada

viiv healthcare ulc - fostemsavir (fostemsavir tromethamine) - tablet (extended-release) - 600mg - fostemsavir (fostemsavir tromethamine) 600mg - miscellaneous antiretrovirals*

Uingereza - Kiingereza - myHealthbox

chiesi limited - beclometasone dipropionate, formoterol fumarate dihydrate. - pressurised inhalation solution. - 200/6 micrograms/metered dose - drugs for obstructive airway diseases; adrenergics, inhalants - fostair is indicated in the regular treatment of asthma where use of a combination product (inhaled corticosteroid and long-acting beta2-agonist) is appropriate: - patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled rapid-acting beta2-agonist or - patients already adequately controlled on both inhaled corticosteroids and long-acting beta2-agonists. fostair is indicated in adults.

Uingereza - Kiingereza - myHealthbox

chiesi gmbh - dipropionate anhydrous, formoterol fumarate dihydrate. - inhalation powder. - 200 micrograms/6 micrograms for metered dose - rugs for obstructive airway diseases; adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics. - fostair nexthaler is indicated in the regular treatment of asthma where use of a combination product (inhaled corticosteroid and long-acting beta2-agonist) is appropriate: - patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short-acting beta2-agonist or - patients already adequately controlled on both inhaled corticosteroids and long-acting beta2-agonists. fostair nexthaler is indicated in adults. note: there are no relevant clinical data on the use of fostair nexthaler for the treatment of acute asthma attacks.

Kanada - Kiingereza - Health Canada

medimmune oncology, inc. - amifostine - powder for solution - 500mg - amifostine 500mg - miscellaneous therapeutic agents

Marekani - Kiingereza - NLM (National Library of Medicine)

doctors foster and smith - iodoform (unii: kxi2j76489) (iodoform - unii:kxi2j76489) - iodoform 1.4 g in 28 g - drs. foster and smith ear powder gives prompt relief from irritated, itching ears of non-parasitic origin. it stops scratching and aids in the inhibition of bacterial growth. eliminates unpleasant ear odors. drs. foster and smith ear powder dries ear discharge and makes it easy to remove. for topical use within the ears. for dogs and cats.